Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology
(Thomson Reuters ONE) -
Esperite (ESP): Patent granted in China for treatment of acute and chronic
inflammatory and autoimmune diseases with EVs technology.
The Cell Factory expands its patent portfolio on extracellular vesicles biologic
drugs in China.
Esperite's (Euronext: ESP) biotech company The Cell Factory has obtained the
patent for use of extracellular vesicles (EVs) in treatment of acute and chronic
inflammatory and autoimmune diseases in China. This allows The Cell Factory
entering into one of the largest markets of advanced therapeutics with its
disruptive technology of the extracellular vesicles products replacing allogenic
MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-
107 for treatment of Crohn's disease and CF-MEV-117 for treatment of drug
resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from
May 31-June 1, 2017.
Zutphen, The Netherlands - 11 May 2017
The Cell Factory, a company of Esperite Group owns the full rights of a broad
international patent family enabling MSC-derived extracellular vesicles (EVs)
use in treatment of autoimmune, chronic and acute inflammatory diseases. The
patents have been already granted in Europe and recently in China. The Cell
Factory is developing the EVs biologic drug products for multiple indications in
immunology, neurology and gastroenterology. The leading products are CF-MEV-107
for treatment of Crohn's disease (drug resistant perianal fistulae) and CF-MEV-
117 for treatment of drug resistant epilepsy in children. The CF-MEV-107 product
is ready for clinical translation and the consortium of leading academic and
clinical teams sponsored by The Cell Factory is preparing the CF-MEV-107 product
for first in man clinical translation in 2017.
The Cell Factory is a biotech company, a subsidy of the Esperite group,
developing highest quality therapeutic tools for affordable regenerative
medicine. The Cell Factory led by Dr. Marcin Jurga is focused on development,
clinical translation and commercialization of the advanced extracellular
vesicles (EVs) biologic drugs and autologous stem cell therapies. The Cell
Factory goal is to become a leader in development and production of
extracellular vesicles drugs in treatment of different indications i.e. graft
versus host disease (GvHD) after solid organ and cell transplantations,
arthritis, multiple sclerosis, cystic fibrosis, stroke, traumatic brain and
spinal cord injury, newborn encephalopathy, and type 1 diabetes among others.
To learn more about ESPERITE Group, or to book an interview with CEO Frederic
Amar: +31 575 548 998 - ir(at)esperite.com or visit the websites at
www.esperite.com and www.genoma.com.
PR patent China:
http://hugin.info/143308/R/2103806/798170.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2017 - 09:27 Uhr
Sprache: Deutsch
News-ID 541788
Anzahl Zeichen: 3618
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 118 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology"
steht unter der journalistisch-redaktionellen Verantwortung von
Esperite N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
